RAMM Pharma Completes Acquisition of Canapar Corp.
June 15, 2021 09:19 ET
|
RAMM Pharma Corp.
TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- Further to its news releases dated May 12 and June 14, 2021, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:...
Canapar Corp. Receives Shareholder Approval for Business Combination With RAMM Pharma
June 14, 2021 07:38 ET
|
RAMM Pharma Corp.; Canapar Corp.
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Further to its news release dated May 12, 2021, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader...
RAMM Pharma to Acquire 100% of Leading Vertically Integrated European Cannabis Company Canapar Corp.
May 12, 2021 13:05 ET
|
RAMM Pharma Corp.
TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and...
RAMM Pharma Receives Federal Pharmaceutical Approval and Registration of NettaVet™ 10% CBD Formulation, a First for Veterinary Medicine
April 20, 2021 07:30 ET
|
RAMM Pharma Corp.
TORONTO, April 20, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM) (OTC: RAMMF), a leader in plant-derived cannabinoid...
RAMM Pharma Commences Sales of NettaPet™ CBD Enriched Super Premium Quality Dog Food with Strong Pre-Order Demand
April 09, 2021 07:30 ET
|
RAMM Pharma Corp.
TORONTO, April 09, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM) (OTC: RAMMF), a leader in plant-derived cannabinoid...
RAMM Pharma Initiates Clinical Trials of its Proprietary NettaVet™ Cannabinoid Formulation for Multiple Pathologies in Animals
March 25, 2021 07:30 ET
|
RAMM Pharma Corp.
TORONTO, March 25, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM) (OTC: RAMMF), a leader in plant-derived cannabinoid...
RAMM Pharma Selected as COVID-19 Vaccine Fulfilment & Distribution Partner by the Uruguayan Ministry of Health
February 23, 2021 07:30 ET
|
RAMM Pharma Corp.
TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...
RAMM Pharma Makes Additional Investment in Canapar & Provides Overview of Strategic Acquisition to Enter European Cannabis Market
January 05, 2021 07:30 ET
|
RAMM Pharma Corp.
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and...
RAMM Pharma Enters European Cannabis Market with Strategic Investment in Canapar Corp.
December 30, 2020 17:27 ET
|
RAMM Pharma Corp.
TORONTO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and...
RAMM Pharma Commences Epifractán™ Sales through Peruvian Pharmacies and Scales up Exports to Brazil
October 08, 2020 07:53 ET
|
RAMM Pharma Corp.
TORONTO, Oct. 08, 2020 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical...